BioVie to give data for epigenetic basis for bezisterim and aging at ARDD 2024

BioVie announced data from an oral presentation at the 11th Aging Research and Drug Discovery Meeting ARDD 2024 being held August 26-30 in Copenhagen, Denmark. The presentation “Bezisterim Effects on Biological Age, Alzheimer’s Epigenetics, and Neurologic Assessments” provided an overview of clinical data to-date on Epigenetic Basis , focusing on various analyses and measurements related to longevity and its ability to affect the biological aging process broadly and chronic low-grade inflammation specifically. The presentation was given by Christopher L. Reading, BioVie’s Senior Vice President, Alzheimer’s Disease Program.”The presented clinical data provides the deepest understanding yet of how bezisterim may work at the gene level to reduce inflammation and impact disease,” said Cuong Do, BioVie’s President and CEO. “The data shows that patients treated with bezisterim experienced a two- to four-year age deceleration advantage when compared to placebo as measured by various biological clocks. The DNA methylation data also explain how bezisterim could modulate the function of specific proinflammatory genes and support the transition of M1 proinflammatory macrophages to the M2 anti-inflammatory state. Most importantly, the data shows bezisterim’s potential ability to control the expression of specific genes in pathways associated with diseases ranging from Parkinson’s and Alzheimer’s to ALS and biological processes ranging from TNF signaling to apoptosis.”.